-
PROVIDERS
REGISTER NOW
AI in oncology: Fundamentals to full integration into your practice
Monday, September 15th
10:00am PT, 12:00pm CT, 1:00pm ET -
LIFE SCIENCES
READ NOW
Q&A: Harnessing generative AI to refine clinical research & drug development
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
06/26/2023
Roswell Park Comprehensive Cancer Center
Researchers from Tempus partnered with the Roswell Park Comprehensive Cancer Center to study aberrations in patients with metastatic non-small cell lung cancer.
FGFR fusions represent a potential mechanism of resistance to EGFR inhibitors. This study characterizes the prevalence of these alterations and the landscape of co-mutations that may be of high interest to drug developers targeting FGFR fusions.
This study was presented at the Targeted Therapies of Lung Cancer Meeting in February 2023.
-
08/29/2025Precision Medicine 2.0: The operating system for oncology R&D
This white paper addresses the persistent challenges in oncology R&D, demonstrating how precision medicine has evolved into a new paradigm built on systems-level understanding and AI-driven insights. Download for a comprehensive overview of Precision Medicine 2.0, its core scientific pillars, enabling technologies, and how R&D organizations can leverage this integrated approach to optimize their cancer research.
Read more -
08/15/2025Tempus’ data solutions for commercialization
Learn how our multimodal real-world data can help quantify new market opportunities, build your value story, and inform your market access strategy.
Read more -
08/15/2025Tempus’ data solutions for clinical development
Learn how our multimodal real-world data can help you optimize trial design, mitigate risk, and inform your companion diagnostic strategy.
Read more